---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-040982"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-09-20T23:59:59+00:00"
generated_at: "2026-05-31T02:45:25.271883+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ChromaDex appoints Ozan Pamir as CFO effective October 21, 2024; James Lee returns to Controller role

## Summary
- Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.
- Annual base salary of $400,000; target bonus 50% of base; option grant with initial value of $360,000.
- Pamir previously CFO of 180 Life Sciences; also held investment banking roles at Ventum Financial.
- Option vests: 1/3 one-year anniversary, rest over 24 months; severance: 9 months' base salary on termination without cause.

## SEC filing metadata
- accession: 0001628280-24-040982
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/cdxc-20240919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-040982
- JSON: https://secwatch.observer/filing/0001628280-24-040982.json
- Plain text: https://secwatch.observer/filing/0001628280-24-040982.txt

## Key facts
- Executive change
  Ozan Pamir was appointed as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Principal Accounting Officer
  source text: On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm
- Executive change
  James Lee changed role as Controller at Niagen Bioscience, Inc..
  - Action: replaced
  - Role: Controller
  source text: Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.